[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559717":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":11,"studyPopulation":11,"armGroups":40,"interventions":52,"overallOfficials":11,"centralContacts":58,"locations":64,"responsibleParty":155,"collaborators":11,"id":157,"slug":11,"hasResults":158,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":11,"eligibilityCriteria":162,"healthyVolunteers":158,"sex":163,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":11,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"GC Biopharma Corp","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Incidences and characteristics of adverse events",null,"up to 108 weeks",[14,18,20,22,24,26,28,30,32],{"measure":15,"description":16,"timeFrame":17},"Maximum concentration in cerebrospinal fluid (CSF)","GC1130A PK parameters","up to 104 weeks",{"measure":19,"description":16,"timeFrame":17},"Area under the concentration-time curve in CSF",{"measure":21,"description":16,"timeFrame":17},"Maximum concentration in serum",{"measure":23,"description":16,"timeFrame":17},"Area under the concentration-time curve in serum",{"measure":25,"description":11,"timeFrame":17},"Change from baseline in CSF heparan sulfate concentration",{"measure":27,"description":11,"timeFrame":17},"Change from baseline in serum heparan sulfate concentration",{"measure":29,"description":11,"timeFrame":17},"Incidence of anti-drug and neutralizing antibodies of GC1130A in CSF",{"measure":31,"description":11,"timeFrame":17},"Incidence of anti-drug and neutralizing antibodies of GC1130A in serum",{"measure":33,"description":11,"timeFrame":17},"Change from baseline in raw scores in cognitive domain of Bayley Scales of Infant and Toddler Development Scores-3rd edition (BSID-III)",{"allocation":35,"interventionModel":36,"interventionModelDescription":11,"primaryPurpose":37,"observationalModel":11,"timePerspective":11,"maskingInfo":38},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":39,"maskingDescription":11,"whoMasked":11},"NONE",[41,46,49],{"label":42,"type":43,"description":11,"interventionNames":44},"Cohort 1","EXPERIMENTAL",[45],"Drug: GC1130A",{"label":47,"type":43,"description":11,"interventionNames":48},"Cohort 2",[45],{"label":50,"type":43,"description":11,"interventionNames":51},"Cohort 3",[45],[53],{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":11},"DRUG","GC1130A","ICV injection",[42,47,50],[59],{"name":60,"role":61,"phone":62,"phoneExt":11,"email":63},"GC Biopharma Corp.","CONTACT","+82312609300","mps3a_clinicaltrial@gccorp.com",[65,88,109,123,140],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"UCSF Benioff Children's Hospital","RECRUITING","Oakland","California","94609","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-122.2708,37.80437,{"lat":77,"lon":76},[80,85],{"name":81,"role":61,"phone":82,"phoneExt":83,"email":84},"Mariam Samara","510-428-3885","4785","Mariam.Samara@ucsf.edu",{"name":86,"role":87,"phone":11,"phoneExt":11,"email":11},"Paul Harmatz, MD","PRINCIPAL_INVESTIGATOR",{"facility":89,"status":67,"city":90,"state":91,"zip":92,"country":71,"countryCode":72,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"University of Minnesota","Minneapolis","Minnesota","55455",{"type":74,"coordinates":94},[95,96],-93.26384,44.97997,{"lat":96,"lon":95},[99,103,107],{"name":100,"role":61,"phone":101,"phoneExt":11,"email":102},"Brenda Diethelm-Okita","612-625-1594","dieth001@umn.edu",{"name":104,"role":61,"phone":105,"phoneExt":11,"email":106},"Melissa Fetterley","612-672-5151","Melissa.Fetterley@fairview.org",{"name":108,"role":87,"phone":11,"phoneExt":11,"email":11},"Chester Whitley, MD",{"facility":110,"status":67,"city":111,"state":112,"zip":11,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"National Center for Child Health and Development","Setagaya City","Tokyo","Japan","JP",{"type":74,"coordinates":116},[117,118],139.64715,35.64188,{"lat":118,"lon":117},[121],{"name":122,"role":87,"phone":11,"phoneExt":11,"email":11},"Motomichi Kosuga, MD",{"facility":124,"status":67,"city":125,"state":126,"zip":11,"country":127,"countryCode":11,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Ajou University Medical Center","Suwon","Gyeongi-do","South Korea",{"type":74,"coordinates":129},[130,131],127.00889,37.29111,{"lat":131,"lon":130},[134,138],{"name":135,"role":61,"phone":136,"phoneExt":11,"email":137},"Bora Lim","+82312194404","115694@aumc.ac.kr",{"name":139,"role":87,"phone":11,"phoneExt":11,"email":11},"Young Bae Sohn, MD",{"facility":141,"status":67,"city":142,"state":11,"zip":11,"country":127,"countryCode":11,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Samsung Medical Center","Seoul",{"type":74,"coordinates":144},[145,146],126.9784,37.566,{"lat":146,"lon":145},[149,153],{"name":150,"role":61,"phone":151,"phoneExt":11,"email":152},"Minji Im, MD","+82234103757","mj33.im@samsung.com",{"name":154,"role":87,"phone":11,"phoneExt":11,"email":11},"Sung Yoon Cho, MD",{"type":156,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100559717",false,"NCT06567769","Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","Inclusion Criteria:\n\n* Participants with documented MPS IIIA diagnosis\n* Participants aged ≥ 12 months and ≤ 18 years\n\nExclusion Criteria:\n\n* Participants with significant non-MPS IIIA related central nervous system impairment\n* Participants with previous complication from intraventricular drug administration\n* Participants with contraindications for MRI scans and for neurosurgery\n* Participants that received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study\n* Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy","ALL","12 Months","18 Years",{"count":167,"type":168},9,"ESTIMATED","INTERVENTIONAL",[171],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).",[174],"Sanfilippo Syndrome Type A",[176,177],"Mucopolysaccharidosis Type III Subtype A","MPS IIIA","2025-08-21",{"date":180,"type":181},"2025-08-28","ACTUAL",{"date":183,"type":181},"2024-11-21",{"date":185,"type":168},"2027-06",{"name":5,"class":6},5]